CALC — CalciMedica, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1534133 ·
Last close
$1.22
Market Cap
$8.41M
52W High
$36.00
52W Low
$1.00
ADV30
75,897
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 0 | — | -4,751,000 | -1,674,000 | 14,294,000 | 4,574,000 | 10,067,000 |
| Jun 2026 | 0 | — | -4,012,000 | -7,652,000 | 19,503,000 | 18,617,000 | 13,990,000 |
| Mar 2026 | 0 | — | -5,611,000 | 4,976,000 | 8,609,000 | 8,164,000 | 9,713,000 |
| Dec 2025 | 0 | — | -4,385,000 | -10,760,000 | 13,591,000 | 11,520,000 | 20,232,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-18,191,000
Investing CF
$-453,000
Financing CF
$17,748,000
CapEx
$-28,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.51
As of
2026-11-15
Balance + Analyst (yfinance extras)
Retained Earnings
$-193,676,000
Inventory
—
Receivables
—
ST Investments
$9,194,000
EBIT TTM
$-13,784,000
Pretax Income TTM
$-15,110,000
Interest Exp TTM
$1,326,000
Analysts
2
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -23,121,000 | -29,562,000 | 13,591,000 | 20,232,000 | -6,641,000 | -21,178,000 |
| Dec 2024 | 0 | -24,204,000 | -13,700,000 | 19,794,000 | 5,384,000 | 14,410,000 | -21,146,000 |
| Dec 2023 | 0 | -38,075,000 | -34,357,000 | 12,185,000 | 4,028,000 | 8,157,000 | -25,730,000 |
| Dec 2022 | 0 | -14,193,000 | -7,824,000 | 3,349,000 | 12,582,000 | -9,233,000 | -11,757,000 |
TTM Snapshot
Revenues TTM
$0
NetIncome TTM
$-21,240,000
OpCashFlow TTM
—
Assets (Latest)
$19,503,000
Forward EPS
$-1.63
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| DARE | Dare Bioscience, Inc. | $8.44M | $0.43 | — |
| VTGN | Vistagen Therapeutics, Inc. | $8.34M | $0.19 | — |
| KYNB | KYNTRA BIO, INC. | $8.26M | $2.04 | — |
| PHIO | Phio Pharmaceuticals Corp. | $8.57M | $0.72 | — |
| MTVA | MetaVia Inc. | $8.24M | $1.25 | — |
News headlines (Yahoo Finance, 1h cache)
What Makes CalciMedica Inc. (CALC) a New Buy Stock
2026-11-12 16:00 · Yahoo
CalciMedica Reports Third Quarter 2026 Financial Results and Provides Clinical & Corporate Updates
2026-11-10 12:00 · Yahoo
CalciMedica to Participate in the Guggenheim 3rd Annual Healthcare Innovation Conference
2026-11-03 13:00 · Yahoo
CalciMedica to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
2026-09-08 11:00 · Yahoo
CalciMedica stock gains 6% as pulmonary hypertension progress offsets Q2 earnings miss
2026-08-11 14:11 · Yahoo
CalciMedica Announces FDA Alignment on Phase 2b Trial Design for Auxora in Acute Pancreatitis and Identifies Disease's First Potential Registrational Endpoints
2026-07-29 11:00 · Yahoo
CalciMedica Announces Clinical Development of Auxora May Proceed Following FDA Review of KOURAGE Trial Interim Safety Data
2026-06-24 11:00 · Yahoo
CalciMedica Announces Private Placement Financing for Up to Approximately $49 Million to Advance Pulmonary Hypertension Program
2026-06-24 11:01 · Yahoo
CalciMedica Reports First Quarter 2026 Financial Results and Provides Clinical & Corporate Updates
2026-05-12 11:00 · Yahoo
CalciMedica Announces One-for-Five Reverse Stock Split
2026-08-27 13:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.